Rigel Pharmaceuticals, Inc.

RIGL Healthcare Biotechnology

Rigel Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $294.3 million, up 64.1% from fiscal 2024. In the quarter to June 2026, revenue fell 22.6%, EPS fell 72.1%, free cash flow fell 230.0% and total debt fell 66.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

45.97 1.28 −2.71%
Market cap
$882.6M
P/E
2.6×
Fwd P/E
7.9×
Dividend yield
—
F-score
6/9
Altman Z
2.70
Beneish M
0.78
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
2.21 1.35 2.12 4.48

+8 more quarters

P/S ratio
2.62 1.66 2.62 1.81
P/FCF ratio
80.77 6.30 10.21 7.52
P/Operating CF
23.66 182.70 35.05 21.26
P/B ratio
1.71 1.25 1.97 4.35
EV/Sales
2.33 1.22 2.17 1.43
EV/EBITDA
7.26 2.91 5.03 3.36
EV/FCF
71.82 4.63 8.45 5.94
Current Ratio
1.94 2.62 2.42 2.28
Net Debt/EBITDA
(3.91) (10.70) (5.63) (3.75)
Debt/Equity
0.00 0.04 0.06 0.25
Earnings Yield
45.17% 74.22% 47.26% 22.34%
Free Cash Flow Yield
1.24% 15.88% 9.79% 13.30%
Free Cash Flow per Share
(2.14) 0.15 1.22 1.33
Book value per Share
22.94 21.72 21.76 6.52
Free Cash Flow
(39.69) 2.73 21.98 24.02
EV/EBIT
7.41 2.94 5.08 3.40
Other line items

Show all line items

Columns are period end dates